Edited by:Peifang Wei Lung cancer is the most lethal solid malignancy in adults worldwide.1 Chimeric antigen receptor(CAR)-T cell therapy has emerged as a promising approach for anti-tumor immunotherapy.2 As of Novemb...Edited by:Peifang Wei Lung cancer is the most lethal solid malignancy in adults worldwide.1 Chimeric antigen receptor(CAR)-T cell therapy has emerged as a promising approach for anti-tumor immunotherapy.2 As of November 2024,the United States Food and Drug Administration has granted market authorization to seven CAR-T products for treating relapsed or refractory hematological neoplasms;however,extending this platform to lung cancer faces formidable obstacles.展开更多
文摘Edited by:Peifang Wei Lung cancer is the most lethal solid malignancy in adults worldwide.1 Chimeric antigen receptor(CAR)-T cell therapy has emerged as a promising approach for anti-tumor immunotherapy.2 As of November 2024,the United States Food and Drug Administration has granted market authorization to seven CAR-T products for treating relapsed or refractory hematological neoplasms;however,extending this platform to lung cancer faces formidable obstacles.
